High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
U.S. electrophysiology growth slowed sharply and standalone WATCHMAN referrals declined in the same window, leaving the rest of Boston Scientific unable to maintain its growth-stock multiple.
Dexcom CEO Jake Leach said he is watching for a decision by the federal health insurance program before the end of the year.
Abbott Laboratories (NYSE:ABT) received FDA De Novo authorization for its Libre Duo 10 Day, described as the first dual glucose ketone monitoring wearable for U.S. patients. The Libre Duo 10 Day is cleared for use in people with diabetes as young as age 2 and is intended to support real time tracking of both glucose and ketone levels. Abbott plans integration of Libre Duo 10 Day with leading insulin pump systems in the U.S. over the coming years as part of its broader diagnostics and digital...
Pfizer Inc. (NYSE:PFE) and Abbott Laboratories (NYSE:ABT) offer investors two very different dividend stories. Pfizer (NYSE:PFE) is working to rebuild growth before major patent expirations arrive, while Abbott (NYSE:ABT) is combining a long dividend-growth record with a more diversified healthcare portfolio. Pfizer (NYSE:PFE) may offer turnaround potential, but Abbott’s (NYSE:ABT) latest results present the steadier […]
On Aug. 26, 2026, a cyberattack halted order processing and shipping at the medical device maker, leaving investors uncertain about the speed of recovery and near-term shipment delays.
For long-suffering owners of Boston Scientific, here’s how to get paid a meaningful cash income now, yours to keep no matter what, in exchange for capping your gains at a higher price.
The U.S. Food and Drug Administration (FDA) on Tuesday approved Abbott Laboratories’ (NYSE:ABT) Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System for diabetes patients aged two and older. The regulatory nod makes the device the first wearable in the U.S. to monitor ketone levels continuously. It also represents the first global system to track blood sugar and ketones simultaneously within a single unit. Clinical Data And De Novo Pathway The agency granted marketing authorization
Aug 26 (Reuters) - Boston Scientific said on Wednesday that a cybersecurity incident had disrupted global operations, including some information systems used to process and ship customer orders.
His AbbVie purchase was a big move into a high-yielding dividend stock.
Three catalysts, one reshuffling, and a Fed that refuses to move
Boston Scientific is back on familiar ground, but the business arriving this time is not the same. Will a history of strong bounces matter more than a future of weaker growth.
ABT edges DXCM on price-target upside and valuation, while both pursue CGM growth through innovation, adoption and strong liquidity.
Abbott Laboratories (NYSE:ABT) has agreed to pay $670 million to settle claims involving about 2,000 people who alleged that its specialized preterm infant formulas contributed to necrotizing enterocolitis (NEC), a serious and potentially fatal bowel disease affecting premature infants. The settlement also resolves Abbott’s appeal of a $495 million verdict involving an Illinois mother, after […]
NVST vs. ABT: Which Stock Is the Better Value Option?
AbbVie and Abbott stand out as strong healthcare investments because they combine established businesses with long-term growth opportunities.
ABT's Diagnostics growth is being reshaped as weaker respiratory testing offsets healthy routine demand and 13% cancer diagnostics growth.
The company has begun a major marketing campaign to support the launch of its MiniMed Flex insulin pump.
MedTech investors are facing an increasingly difficult choice. On one side is Abbott Laboratories (NYSE:ABT), a diversified healthcare company steadily expanding across diagnostics, medical devices, and nutrition. On the other hand is Intuitive Surgical (NASDAQ:ISRG), the undisputed leader in robotic surgery, whose premium valuation reflects expectations for years of continued growth. Both companies delivered strong […]
In August 2026, Abbott Laboratories agreed to pay approximately US$670 million to resolve the Gill case and around 2,000 additional necrotizing enterocolitis-related claims tied to its preterm infant formulas, without admitting liability and following several favorable court rulings for formula manufacturers. This large settlement trims a single, very large jury award while providing greater clarity on Abbott’s remaining infant-formula litigation exposure and case mix. We’ll now explore how...
Healthcare investors are often faced with a choice between companies that generate steady growth across diversified businesses and those positioned to benefit from improving industry conditions. Abbott Laboratories (NYSE:ABT) and Thermo Fisher Scientific (NYSE:TMO) represent those two approaches. Abbott (NYSE:ABT) continues to deliver broad-based growth across diagnostics, medical devices, and nutrition, while Thermo Fisher (NYSE:TMO) […]
Legal settlement reshapes the risk picture for Abbott Laboratories stock Abbott Laboratories (ABT) has agreed to resolve the Gill case and about 2,000 related necrotizing enterocolitis claims linked to its preterm infant formulas for roughly US$670 million, reframing investors’ view of its legal overhang. See our latest analysis for Abbott Laboratories. Recent trading shows momentum building in Abbott Laboratories stock, with the share price up 13.18% over 30 days and 33.44% over 90 days,...
These two high-quality dividend payers have had very different fortunes recently.
Abbott Laboratories (NYSE:ABT) on Friday reached a significant agreement with three law firms to resolve the Gill lawsuit alongside claims from roughly 2,000 individuals.These disputes center around the company’s specialty infant formulas for premature babies and allegations connecting the products to necrotizing enterocolitis (NEC), a severe inflammatory intestinal disease affecting underdeveloped infants.In July 2024, a St. Louis jury delivered a $495 million verdict against the health care co
Two healthcare innovators, MiniMed Group, Inc. (NASDAQ:MMED) and Abbott Laboratories (NYSE:ABT), hit the spotlight this August with a milestone partnership. On August 17, MiniMed announced that its MiniMed Flex system is commercially shipping in the U.S., integrated with Abbott’s Instinct continuous glucose sensor. This collaboration marks a major leap in diabetes tech, pairing MiniMed’s smallest, […]
The bulk settlement relates to the Gill lawsuit, in which a Missouri jury ordered the company to pay $495 million in damages after determining it failed to warn that its formula for preterm infants increased the risk for a bowel disease.
Healthcare stocks declined Thursday afternoon, with the NYSE Healthcare Index decreasing 0.7% and th
The Seattle-based company will bring 300 to 500 jobs to Austin, Texas as it build a multibillion-dollar robotics manufacturing facility.
MMED's MiniMed Flex is now shipping in the U.S. with Abbott's 15-day Instinct sensor, pairing discreet app control with automated insulin delivery.
IDEXX raises its 2026 EPS outlook as recurring diagnostics growth, wider margins and international expansion offset softer U.S. veterinary traffic.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.